**Background**
Liver diseases, including nonalcoholic fatty liver disease (NAFLD) and hepatocarcinoma, remain significant global health challenges due to their progression toward inflammation and fibrosis. The liver’s susceptibility to oxidative stress and lipid accumulation necessitates the development of agents with potent antioxidant and anti-inflammatory properties. In the search for natural therapeutic compounds, flavonolignans have gained attention for their ability to modulate cellular apoptosis and protect hepatic tissues from chemical and metabolic injury. Silybin, a primary active component of silymarin, has demonstrated a broad spectrum of pharmacological effects, including the inhibition of tumor growth and the reduction of hepatic steatosis. Therefore, we will introduce a potent flavonolignan with diverse biological activities – Silybin.
**Definition**
Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds that exhibits hepatoprotective, antioxidant, anti-inflammatory, and anti-cancer activity.
**In Vitro and In Vivo Studies**
The Silybin biological activity has been extensively documented across various cell lines and animal models. Silybin in vitro studies using HepG2 cells demonstrated growth inhibition in a time- and dose-dependent manner (0-200 mM; 72 h) with an IC50 of 68 μM. Specifically, treatment with 68 μM Silybin for 72 hours induced apoptosis in 60% of cells, increased the G1-phase population by approximately 22%, decreased the S-phase population by 47%, and induced AKT activity inhibition. Furthermore, Silybin has shown antiproliferative effects against human DU145 cells (IC50 = 93.34 μM) and HCT-116 cells (IC50 = 50 μM), while exhibiting neuroprotective activity in mouse HT22 cells (EC50 > 10 μM). In terms of hepatoprotection, it inhibited CCl4-induced toxicity in HepG2 cells (EC50 = 45 μM) and D-galactosamine/TNF-alpha-induced cytotoxicity in mouse hepatocytes (IC50 = 15-82.4 μM).
Regarding Silybin In Vivo applications, research using male C57BL/6J mice with nonalcoholic fatty liver disease (NAFLD) showed that intragastric administration of Silybin (50, 100 mg/kg/day) for the last 4 weeks significantly lowered both serum and hepatic lipid accumulation. These findings highlight the compound’s potential in treating metabolic liver disorders. For researchers seeking Silybin technical information or high-quality reagents, utilizing a reliable Silybin supplier ensures consistent experimental results. In conclusion, Silybin is a versatile flavonolignan that serves as a powerful tool for studying Silybin Cancer research and hepatoprotective mechanisms.
Keywords
Silybin, 802918-57-6, Silibinin, Apoptosis, milk, thistle, hepatoprotective, antioxidant, anti-inflammatory, anti-cancer, HepG2, G1-phase, S-phase, AKT, Inhibitor
References
[1] Silvia Zappavigna, et al. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. Int J Mol Sci. 2019 May 3;20(9):2190.
[2] Runbin Sun, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020 Mar;123:109721.